Summit Therapeutics (NASDAQ: SMMT) is managed by institutional shareholders to the tune of 1.59%, insiders to the tune of 88.20%, and retail investors to the tune of 10.22%. It is currently 250% higher than its 52 week low and 56.08% lower than its 52 week high. The 52 week high and low of Summit Therapeutics were each $5.26. The current share price for Summit Therapeutics is $2.31. The NASDAQ symbol for Summit Therapeutics trading tools is SMMT. Under the ticker SMMT, Summit Therapeutics is traded on the NASDAQ. The business is headquartered in Cambridge, Massachusetts, and was established in 2003. Ridinilazole, an oral small molecule antibacterial that is now undergoing Phase III clinical studies for the management of CDI, is the company's principal product candidate.Īdditionally, it provides the DDS-04 series for the prospective treatment of infections caused by the Enterobacteriaceae and SMT-738 for the management of multidrug resistant infections, primarily carbapenem-resistant Enterobacteriaceae infections. It performs clinical initiatives concentrating on the infection caused by Clostridioides difficile (CDI). finds, creates, and markets drugs to treat infectious conditions in the US and Latin America. A biopharmaceutical business called Summit Therapeutics Inc. We can start the information about SMMT stock by introducing the company.
0 Comments
Leave a Reply. |